Lexaria Bioscience Corp (LEXX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.35M
Last updated: Nov 17, 2026 at 11:05 AM ET
Lexaria Bioscience Corp (LEXX) Financials: Revenue, Profit and Cash Flow
Lexaria Bioscience reported revenue of $705.92K for the fiscal year ended Aug 31, 2025, up 52.0% from the year before. That year, net income was -$11.90M with a net margin of -1686.0%, operating cash flow was -$10.45M and free cash flow was -$10.48M. The quarter ended May 31, 2026 had revenue of $0 and net income of -$1.99M.
Revenue and Margins
Over the 9 years to Aug 2025, revenue grew from $40.72K, a compound annual rate of 37.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Aug 2025 | $705.92K | +52.0% | 99.6% | -1683.0% | -1686.0% |
| Aug 2024 | $464.28K | +105.2% | 99.0% | -1239.2% | -1248.2% |
| Aug 2023 | $226.21K | -11.4% | 86.1% | -2888.5% | -2946.4% |
| Aug 2022 | $255.40K | -64.7% | 71.9% | -2591.7% | -2846.3% |
| Aug 2021 | $722.74K | +87.9% | 75.7% | -786.8% | -557.2% |
| Aug 2020 | $384.54K | +72.7% | 56.0% | -1078.9% | -1023.0% |
| Aug 2019 | $222.61K | -48.6% | 89.7% | -1823.7% | -1841.5% |
| Aug 2018 | $433.29K | +580.9% | 94.2% | -1523.3% | -1523.0% |
| Aug 2017 | $63.64K | +56.3% | 53.3% | -2914.6% | -2937.3% |
| Aug 2016 | $40.72K | N/A | -12.0% | -3023.1% | -2983.4% |
Income Statement
In the fiscal year ended Aug 2025, the net loss widened from the year before. In the quarter ended May 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $705.92K | $464.28K | $226.21K | $255.40K | $722.74K | $384.54K | $222.61K | $433.29K | $63.64K | $40.72K |
| Cost of revenue | $2.72K | $4.82K | $31.50K | $71.84K | $175.35K | $99.38K | $22.89K | $25.18K | $29.75K | $45.62K |
| Gross profit | $703.20K | $459.46K | $194.71K | $183.56K | $547.39K | $215.41K | $199.72K | $408.10K | $33.89K | -$4.90K |
| Research and development | $8.24M | $2.36M | $3.67M | $1.84M | $1.26M | $387.07K | $555.73K | $492.86K | $54.19K | $9.02K |
| Operating income | -$11.88M | -$5.75M | -$6.53M | -$6.62M | -$5.69M | -$4.15M | -$4.06M | -$6.60M | -$1.85M | -$1.23M |
| Net income | -$11.90M | -$5.80M | -$6.66M | -$7.27M | -$4.03M | -$3.93M | -$4.10M | -$6.60M | -$1.87M | -$1.21M |
| EBITDA | -$11.82M | -$5.73M | N/A | N/A | -$4.02M | -$4.00M | -$4.00M | -$6.60M | N/A | N/A |
Quarterly
| Line item | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $20.00K | $0 | $174.00K | $174.00K | $174.00K | $183.92K | $84.00K | $84.00K | $145.00K | $151.28K | -$3.43K |
| Gross profit | $0 | $20.00K | -$24.20K | $174.00K | $174.00K | $174.00K | $181.20K | $84.00K | $84.00K | $145.00K | $146.46K | -$3.43K |
| Operating income | -$1.99M | -$1.45M | -$1.57M | -$2.69M | -$3.75M | -$2.75M | -$2.69M | -$2.20M | -$1.74M | -$668.00K | -$1.14M | -$1.07M |
| Net income | -$1.99M | -$1.45M | -$1.60M | -$2.70M | -$3.79M | -$2.71M | -$2.70M | -$2.18M | -$1.78M | -$649.54K | -$1.18M | -$1.24M |
Balance Sheet
As of Aug 2025, cash and equivalents exceeded short-term debt of $30.42K by $1.77M.
Annual
| Line item | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.18M | $8.87M | $3.08M | $7.83M | $13.27M | $2.83M | $2.68M | $2.43M | $2.86M | $566.64K |
| Current assets | $3.47M | $7.90M | $2.20M | $6.98M | $12.44M | $1.93M | $1.82M | $2.28M | $2.80M | $510.17K |
| Cash and equivalents | $1.80M | $6.50M | $1.35M | $5.81M | $10.92M | $1.29M | $1.29M | $1.73M | $2.53M | $93.41K |
| Total liabilities | $1.57M | $1.21M | $403.91K | $201.44K | $203.26K | $345.98K | $184.51K | $43.64K | $92.35K | $478.88K |
| Short-term debt | $30.42K | $28.05K | $27.79K | $42.59K | $47.33K | $36.04K | N/A | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $30.67K | N/A | N/A | N/A | N/A |
| Shareholder equity | $2.99M | $8.04M | $3.04M | $7.95M | $13.27M | $2.53M | $2.38M | $2.39M | $3.01M | $266.05K |
Quarterly
| Line item | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.78M | $6.49M | $6.05M | $4.18M | $6.74M | $8.68M | $9.79M | $8.87M | $10.02M | $6.35M | $3.63M | $3.08M |
| Total liabilities | $437.09K | $277.00K | $1.53M | $1.57M | $1.57M | $1.92M | $399.72K | $1.21M | $271.38K | $204.20K | $254.04K | $403.91K |
| Cash and equivalents | $3.48M | $5.13M | $4.28M | $1.80M | $4.59M | $6.47M | $8.08M | $6.50M | $8.46M | $4.71M | $1.95M | $1.35M |
| Shareholder equity | $4.74M | $6.60M | $4.91M | $2.99M | $5.55M | $7.14M | $9.77M | $8.04M | $10.12M | $6.52M | $3.74M | $3.04M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Aug 2025.
Annual
| Line item | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 | Aug 2021 | Aug 2020 | Aug 2019 | Aug 2018 | Aug 2017 | Aug 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.45M | -$4.96M | -$5.88M | -$4.88M | -$3.99M | -$2.62M | -$3.01M | -$2.52M | -$1.55M | -$660.86K |
| Capital expenditures | $24.64K | $43.02K | $169.61K | $49.19K | $79.49K | $33.65K | $769.16K | $85.40K | $9.70K | $20.10K |
| Free cash flow | -$10.48M | -$5.00M | -$6.05M | -$4.93M | -$4.07M | -$2.65M | -$3.77M | -$2.60M | -$1.56M | -$680.96K |
| Investing cash flow | -$243.02K | -$188.60K | -$169.61K | -$180.64K | $193.88K | -$26.84K | -$769.16K | -$155.40K | -$9.70K | -$20.10K |
| Financing cash flow | $6.05M | $10.32M | $1.59M | -$44.60K | $13.42M | $2.65M | $3.33M | $1.87M | $4.00M | $514.29K |
Quarterly
| Line item | May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.64M | -$2.16M | -$984.10K | -$2.64M | -$3.58M | -$1.50M | -$2.73M | -$1.89M | -$1.27M | -$619.61K | -$1.18M | -$1.62M |
| Capital expenditures | $26.25K | $55.91K | $5.10K | $14.61K | $19.44K | $27.89K | $37.80K | $69.59K | $22.00K | $56.99K | $40.03K | $68.44K |
| Free cash flow | -$1.66M | -$2.22M | -$989.20K | -$2.66M | -$3.60M | -$1.53M | -$2.76M | -$1.96M | -$1.29M | -$676.60K | -$1.22M | -$1.69M |
Frequently Asked Questions About LEXX
What is Lexaria Bioscience's annual revenue?
Lexaria Bioscience reported revenue of $705.92K for the fiscal year ended Aug 31, 2025.
How fast is Lexaria Bioscience's revenue growing?
Revenue was up 52.0% for the fiscal year ended Aug 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 40.3%.
Is Lexaria Bioscience profitable?
No. Lexaria Bioscience reported net income of -$11.90M for the fiscal year ended Aug 31, 2025, with a net margin of -1686.0%.
How much free cash flow does LEXX generate?
For the fiscal year ended Aug 31, 2025, operating cash flow of -$10.45M minus capital expenditures of $24.64K produced free cash flow of -$10.48M.
How much debt does Lexaria Bioscience have?
The balance sheet dated Aug 31, 2025 reported short-term debt of $30.42K and cash and equivalents of $1.80M.
LEXX pages: Overview, Earnings, Financials